112.00 -0.43 (-0.38%)
Pre-Market: 7:00AM EST
|Bid||108.83 x 900|
|Ask||112.47 x 800|
|Day's Range||112.33 - 118.20|
|52 Week Range||102.10 - 140.77|
|Beta (3Y Monthly)||1.12|
|PE Ratio (TTM)||164.13|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||164.35|
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11. Neurocrine stock has hit its 52-week low of $64.72. Neurocrine stock was trading at $103.0 at the close of market on November 12, and it reached $85.69 on December 11, representing a ~17% fall in the month.
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen
Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ a complex analysis to determine the best stocks to invest in. A particularly […]
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Acadia Healthcare (ACHC) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Amgen's (AMGN) BiTE immunotherapy candidates, namely AMG 420 and AMG 330 show positive results in early-stage studies. AMG 420 gets a fast track designation from the FDA
Global Blood Therapeutics (GBT) announces FDA nod for an accelerated approval pathway for voxelotor as a treatment for sickle cell disease. Stock rallies.
- First Conference Presentation of Results for ALXN1210 in Patients on Soliris® at ASH -
The FDA's BRUDAC committee will review Amgen (AMGN) and its European partner UCB's BLA for Evenity so that the candidate gets approved for treating osteoporosis in postmenopausal women.
Immunomedics (IMMU) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.
Aileron Therapeutics (ALRN) signs a clinical trial collaboration contract with Pfizer to study the combo of Aileron's ALRN-6924 and Pfizer's Ibrance for treating MDM2-amplified cancers. Stock rises.
Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.
Rocket Pharmaceuticals (RCKT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.